steroid-dependent urticariaOmalizumab has been recognized to be effective in the treatment of chronic spontaneous urticaria (CSU). The Italian Medicines Agency authorizes two omalizumab courses, only for patients with CSU unresponsive to antihistamines, and this schedule may limit omalizumab use. ...
Long-term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking. OBJECTIVE To evaluate the effectiveness, safety, estimated omalizumab treatment duration and its predic...
Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol 2008;121:784.Spector SL, Tan RA. Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol. 2008;121:784.Spector SL, Tan RA. Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol. 2008; 121...
In people with chronic spontaneous urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection. In people with food allergy: injection site reactions and fever. These are not all the possible side effects of XOLA...
Efficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled TrialEfficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Bl...
The most common side effects of XOLAIR in people with chronic spontaneous urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection. These are not all the possible side effects of XOLAIR. Call your doctor for...
Background and Design: Humanized monoclonal antibody omalizumab was developed for the treatment of moderate-to-severe asthma. However, recently, reports on the successful use of omalizumab in the treatment of resistant chronic urticaria are increasing in the literature. ...
[Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases]. Introduction: Approximately 50% of chronic urticaria cases do not respond adequately to conventional doses of antihistamines, so a number of other therapeu... LS Dí...
In 2003, Xolair® was approved for the treatment of moderate to severe persistent allergic asthma, and is now also approved for the treatment of chronic spontaneous urticaria (CSU) (Chang et al., 2015; Maurer et al., 2013; Zhao et al., 2016). In addition, more than 150 clinical ...
Based on the experience of many researchers, omalizumab is emerging as a novel treatment for certain types of spontaneous refractory chronic urticaria and has shown promising results in this setting. The drug has a good safety profile and the main limitation is its high cost....